Compare FLYW & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | BCRX |
|---|---|---|
| Founded | 2009 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2021 | 1995 |
| Metric | FLYW | BCRX |
|---|---|---|
| Price | $12.53 | $7.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $15.47 | ★ $20.82 |
| AVG Volume (30 Days) | 1.7M | ★ 3.1M |
| Earning Date | 05-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | 63.56 |
| EPS | ★ 0.11 | 0.08 |
| Revenue | ★ $623,025,000.00 | $25,186,000.00 |
| Revenue This Year | $14.26 | $40.21 |
| Revenue Next Year | $15.75 | $6.06 |
| P/E Ratio | $113.82 | ★ $94.38 |
| Revenue Growth | ★ 26.59 | N/A |
| 52 Week Low | $8.20 | $6.00 |
| 52 Week High | $15.25 | $11.31 |
| Indicator | FLYW | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 66.45 |
| Support Level | $12.47 | $6.56 |
| Resistance Level | $13.18 | $8.11 |
| Average True Range (ATR) | 0.52 | 0.26 |
| MACD | 0.23 | 0.12 |
| Stochastic Oscillator | 94.17 | 71.83 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.